AIRA Sciences
AIRA Sciences offers AIR-DS Lung, a non-invasive cheek-swab test that uses infrared spectroscopy and AI to identify lung cancer biomarkers, supporting earlier detection. The UKCA-marked device is designed to fit into existing clinical workflows without requiring blood, specialized collection equipment, or temperature-controlled specimen handling. The company is backed by prospective clinical evidence from over 500 patients and is preparing a US laboratory developed test launch.
- Healthcare Technology
- Medical Devices
- Artificial Intelligence
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Current lung cancer detection methods face significant challenges, including low patient compliance and high false positive rates due to benign nodules. Only 30% of cancers are detected before stage III, limiting early intervention opportunities and increasing mortality risk.
Solution
AIRA Sciences provides AIR-DS Lung, a non-invasive early detection device that uses infrared spectroscopy combined with AI to identify lung cancer biomarkers from a simple cheek swab. The platform eliminates the need for needles, discomfort, or genetic analysis, making cancer screening simple and accessible. The device is UKCA approved, ISO 13485 and IEC 62304 certified, and supported by prospective clinical evidence from over 500 patients. The company is currently running RADICAL-REACT, a multi-site UK clinical performance evaluation study, while preparing for a US LDT launch and FDA submission, with a roadmap to expand beyond lung cancer to other cancer indications.
Target Audience
Primary customers are healthcare systems, hospitals, and clinical laboratories seeking non-invasive cancer screening tools, as well as patients at risk for lung cancer who need accessible early detection options.
Features
- Non-invasive cheek swab sampling that requires no needles, discomfort, or genetic analysis
- Infrared spectroscopy technology combined with AI algorithms to detect cancer biomarkers
- UKCA approved and ISO 13485 and IEC 62304 certified medical device
- Equally accurate for stage I or stage IV cancer cases, enabling early detection
- Two granted global patent families protecting the core technology platform
- Care pathway optimization that reduces pressure on radiology departments with proven net monetary benefit
- Does not require blood, temperature-controlled specimen handling, or specialized collection equipment
- Designed to fit into existing clinical workflows and sites of care